IP Library › Granted Patent US 10,342,842
Granted Patent B2
US 10,342,842 · App. 15/160,381 · Granted Jul 9, 2019

Pharmaceutical compositions having antibacterial, antiviral, and other immunostimulatory activities

Inventors: Ravshan I. Ataullakhanov (Moscow, RU); Aleksey V. Pichugin (Moscow, RU); Tatyana M. Melnikova (Moscow, RU); Rakhim M. Khaitov (Moscow, RU)
Assignee: 9541659 Canada Inc.
A61K36/81A01N65/38A61K31/715A61K38/02A61K38/00A61K2236/15A61K2236/331A61K2236/50A61K2236/51A61K2236/53B01D11/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,342,842
App. No.
15/160,381
Granted
Jul 9, 2019
Kind
B2
Abstract

A method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, particularly towards dendritic cells is proposed, provides for using the chopped potato sprouts as plant raw materials are extracted with water, then the aqueous extract is centrifuged, a salt agent is added, and the obtained saline solution is then concentrated using ultrafiltration through a 300-kD filter, then the solution is frozen for 24 hours, thawed, and filtered, and the pellet thus obtained is removed, and the raw peptidoglycan is precipitated from the solution by using an acidic salt agent and is further re-solubilized with alkali, then the alkaline solution is dialyzed against distilled water on a 12 kD filter, and the peptidoglycan having a molecular weight of 500 kD to 17000 kD is purified from the resulting solution using gel permeation chromatography.

Claims (12)

1. A pharmaceutical composition comprising a substance and a pharmaceutically acceptable carrier or filler, wherein the substance has antimicrobial and antiviral activities, and immunostimulatory activities towards dendritic cells, and wherein the substance comprises:

(i) 40-60% (w/w) polysaccharide, wherein the polysaccharide comprises the following structure:

wherein m=3-5 and every second α-L-Rhap residue bears an R substituent,

R is a monosaccharide or an oligosaccharide comprising β-D-galactopyranose and optionally comprising α-L-arabinofuranose

and the polysaccharide portion comprises a weight ratio of rhamnose to galacturonic acid of 1:6 to 1:4;

(ii) 4-20% (w/w) peptide; and

(iii) 2-7% (w/w) lipid.

2. The pharmaceutical composition of claim 1 , wherein the molecular weight of the substance is 500 kDa to 17,000 kDa.

3. The pharmaceutical composition of claim 1 , wherein the polysaccharide does not comprise glucose.

4. The pharmaceutical composition of claim 1 , wherein the substance is isolated from plant materials from a plant of the Solanaceae family.

5. The pharmaceutical composition of claim 1 , wherein the substance is isolated from potato sprouts.

6. The pharmaceutical composition of claim 1 , wherein R is an oligosaccharide comprising β-D-galactopyranose and α-L-arabinofuranose.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2018
From: ATAULLAKHANOV, RUSTAM R.
To: 9541659 CANADA INC.
Reel/Frame 045081/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2016
From: SILEZIA GROUP PTE. LTD; ATAULLAKHANOV, RUSTAM R.
To: ATAULLAKHANOV, RUSTAM R.
Reel/Frame 038772/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2016
From: ATAULLAKHANOV, RAVSHAN I.; PICHUGIN, ALEKSEY V.; MELNIKOVA, TATYANA M.; KHAITOV, RAKHIM M.
To: SILEZIA GROUP PTE. LTD; ATAULLAKHANOV, RUSTAM R.
Reel/Frame 038771/0813 →
Priority Claims (1)
RU 2013151824 · Nov 21, 2013 · national
Continuity (2)
Continuation PCTRU2014000541 · Jul 22, 2014
Related Publication 20160263175A1 · Sep 15, 2016